Employer file: Syneos Health, a merger inside a buyout

Syneos Health is a company defined by deals: it was created by a merger and then swallowed by a buyout, and its employee sentiment reflects the turbulence that combination tends to produce. This file separates the documented facts from the anonymous sentiment.

The facts

Syneos was formed in 2017 from the merger of INC Research and inVentiv Health, combining a clinical CRO with a commercial and contract-sales organization under one roof. In September 2023 it was taken private for about $7.1 billion, at $43 a share, a 24 percent premium, by a consortium of Elliott Investment Management, Patient Square Capital, and Veritas Capital. It is headquartered in Morrisville, North Carolina, employs roughly 27,000 to 28,000 people across some 110 countries, and is led by CEO Costa Panagos.

Two structural facts shape how to read it. First, it is now private-equity owned, with the cost-discipline incentives that ownership brings. Second, it carries the integration burden of both its original 2017 merger and its 2023 take-private, which is a lot of organizational change layered on one company.

The sentiment

On employee sentiment, again from self-selected anonymous reviews rather than a measurement, Syneos sat around 3.7 out of 5 on Glassdoor in July 2026, with 67 percent of reviewers recommending it. The positives track the industry norm: flexibility, remote work, and a deep bench of talented people, with the legacy INC Research culture often praised. But the dominant negative theme is specific and consistent: frequent layoffs since the 2023 acquisition, along with management indecision and complaints about favoritism.

That layoff theme is worth taking seriously precisely because it is consistent with the structure. A private-equity consortium that pays $7.1 billion for a company will run it for efficiency, and in a labor-heavy services business efficiency means headcount. Employees reporting repeated reductions since the buyout is exactly what the ownership model predicts. It is sentiment, so weigh it as such, but it is sentiment that matches the incentives.

How to read it

Syneos is the clearest case in the group of the private-equity-plus-merger combination, and the reading follows from that. If you are considering it, the questions are about stability: which functions have absorbed the cuts, whether your role overlaps with something the combined company already has, and where the consortium is in its ownership horizon. The talent and flexibility that reviewers praise are real assets; the recurring layoff theme is a real risk. Both belong in the decision.

What the file cannot tell you

The ownership history and the rating tell you the structure and the mood. They cannot tell you what Syneos pays for your specific role, how deep the post-buyout cuts actually ran in your function, or whether the reductions are finished or ongoing. Those answers live only with the people inside, and because the company is private, the public record is especially thin. If you work at Syneos or left in one of the reductions, add your datapoint, and give the next person the picture the filings cannot.